Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study.
Daniele PastoriPaul R J AmesMassimo TriggianiAntonio CiampaVittoria CammisottoRoberto CarnevalePasquale PignatelliTommaso Buccinull On Behalf Of The Athero-Aps Study GroupPublished in: Journal of clinical medicine (2021)
HFpEF is detectable in a relevant proportion of APS patients. The role of aPL in the pathogenesis and prognosis of HFpEF needs further investigation.